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Abstract
Background Risk assessment strategies, such as using the American Society of Anesthesiologists (ASA) physical
status classification, attempt to identify surgical high-risk patients. Soluble urokinase plasminogen activator receptor
(suPAR) is a biomarker reflecting overall systemic inflammation and immune activation, and it could potentially
improve the identification of high-risk surgical patients.
Methods We included patients acutely admitted to the emergency department who subsequently underwent surgery
within 90 days of admission. Patients were stratified into low-risk or high-risk groups, according to ASA classifi-
cation (ASAlow: ASA I–II; ASAhigh: ASA III–VI) and suPAR level, measured at admission (suPARhigh above and
suPARlow below 5.5 ng/ml), respectively. Pre-specified complications were identified in national registries and
electronic medical records. The association between ASA classification, suPAR level, CRP and the rate of post-
operative complications was analyzed with logistic regression and Cox regression analyses, estimating odds ratios
and hazard ratios (HRs).
Results During 90-day follow-up from surgery, 31 (7.0%) patients died and 158 (35.6%) patients had postoperative
complications. After adjusting for age, sex, and ASA classification, the HR for 90-day postoperative mortality was
2.5 (95% CI 1.6–4.0) for every doubling of suPAR level. suPAR was significantly better than CRP at predicting
mortality and all complications (P = 0.0036 and P = 0.0041, respectively). Combining ASA classification and
suPAR level significantly improved prediction of mortality and the occurrence of a postoperative complication within
90 days after surgery (P\ 0.0001).
Conclusion Measuring suPAR levels in acutely admitted patients may aid in identifying high-risk patients and
improve prediction of postoperative complications.
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Introduction
Continuously optimizing treatment of surgical patients has
reduced the incidence of postoperative complications, but
more than one third of in-hospital complications remain
related to surgical procedures [1], although these are often
preventable [2].
The American Society of Anesthesiologists (ASA)
physical status classification is a simple six-point scale
used in the preoperative setting to assess the surgical
patients’ overall physical status [3]. The ASA classification
has been shown to be a good predictor of mortality and
other complications after surgery [4–9]. In many countries,
the ASA classification remains the only preoperative risk
assessment tool used systematically, even though it was
never intended as a risk assessment tool [10].
Adding biomarkers to the preoperative risk assessment
has shown possible advantages in predicting specific
postoperative complications [11–13]. One biomarker with
potential as a risk marker for surgical patients [14, 15] is
the soluble urokinase plasminogen activator receptor
(suPAR). suPAR is the soluble form of uPAR, a surface
receptor expressed on immune cells, endothelial cells, and
cancer cells. In both medical and surgical patients, suPAR
levels are correlated with systemic inflammation and
immune activation [16], and it is a risk marker associated
with mortality [17–20], duration of hospital stay, Charlson
Comorbidity Index [18, 20], and a variety of acute and
chronic conditions, such as chronic kidney disease [21],
pneumonia [14], prosthetic joint infection [15], cancer,
noninsulin-dependent diabetes mellitus and cardiovascular
disease [17]. Whether the broadly applicable and non-
specific biomarker suPAR can add predictive value to
existing preoperative risk assessment has, to our knowl-
edge, not previously been investigated.
We hypothesized that suPAR could add predictive value
to the existing preoperative risk assessment of surgical
patients. Thus, the aim of this study was to examine
whether the suPAR level measured at admission to the
emergency department could add predictive value to the
ASA score in acutely admitted patients undergoing surgical
procedure within 90 days of admission.
Methods
Study participants
This study is a sub-group analysis of the prospective
observational study, TRIAGE, which included 6005 acute
surgical and medical admissions at North Zealand Hospital,
Denmark, between September 5 and December 6, 2013
[22]. Patients were included consecutively. Admission, and
thereby inclusion in the study, was defined as referral to a
bed and blood samples drawn in the ED. Obstetric patients
and patients B 17 years were not included due to direct
admission to the Department of Obstetrics and the Pediatric
ED, respectively. Patients deemed eligible for this study
had surgical intervention within 90 days of admission.
Data collection
Data from the TRIAGE study database were supplemented
with information about surgery obtained by reviewing
electronic medical records. Surgical procedures were reg-
istered, coded according to the Danish National Healthcare
Classification System (SKS), to assess surgical specialty
and the type of surgical procedure. Surgical procedures
were defined as: Minor, e.g., diagnostic laparoscopy,
arthroscopy, inguinal hernia repair, endoscopic retrograde
cholangiopancreatography with papillotomy; moderate,
e.g., cholecystectomy, primary and revision hip and knee
arthroplasty, minor resection of gastrointestinal tract,
laparoscopic gastrointestinal procedure; major, e.g., trauma
surgery, major bowel resection, major orthopedic surgery,
and spinal reconstruction. ASA classification was extracted
from the Danish Anesthesia Database (DAD) along with
information about smoking, alcohol consumption, and
body mass index (BMI), and information about vital status
at follow-up was retrieved from the Civil Registration
System, using the patients’ unique personal identification
numbers.
suPAR analysis
Blood samples were drawn from all patients at admission,
and EDTA plasma was stored at - 80 C until later mea-
surement. suPAR levels were measured using the
suPARnostic AUTO flex ELISA (ViroGates A/S, Den-
mark) according to manufacturer’s instructions.
ASA classification
Prior to surgery all patients were classified by an anes-
thesiologist into six different categories, according to their
physical status [3, 23, 24].
Endpoints
The primary endpoint was mortality within 90 days after
surgery. The secondary endpoints were postoperative
complications within 90 days after surgery defined as in
the SURPAS studies [25–27], with the inclusion of
atelectasis and ileus, resulting in 22 possible postoperative
complications.
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Table 1 Baseline characteristics of surgical patients according to suPARlow/high (above or below 5.5 ng/ml) and ASAlow/high groups (ASA I/II
and III or above)
Variable suPARlow suPARhigh P ASAlow ASAhigh P
n (%) 297 (66.9%) 147 (33.1%) 327 (73.6%) 117 (26.4%)
Sex, n (%)
Female 154 (51.9) 90 (61.2) 0.06 178 (54.4) 66 (56.4) 0.71
Age, mean (SD) 54.7 (20.3) 73.4 (15.9) \0.0001 55.6 (20.8) 75.6 (12.4) \0.0001
Specialty, n (%)
General surgery 142 (47.8) 42 (28.6) 152 (46.5) 32 (27.4)
Orthopedic surgery 103 (34.7) 81 (55.1) 122 (37.3) 62 (52.9)
Other 52 (17.5) 24 (16.3) \0.0001 53 (16.2) 23 (19.7) 0.0013
Surgical intervention, n (%)
Minor 209 (70.4) 66 (44.9) 235 (71.9) 40 (34.2)
Moderate 84 (28.3) 79 (53.7) 91 (27.8) 72 (61.5)
Major 4 (1.4) 2 (1.4) \0.0001 1 (0.3) 5 (4.3) \0.0001
BMI (kg/m2), mean (SD) 25.4 (5.6) 24.0 (6.5) 0.12 25.2 (5.8) 24.2 (6.3) 0.14
Preoperative SIRS/sepsis, n (%)
No 291 (97.9) 132 (89.8) 320 (97.9) 103 (88.0)
SIRS 3 (1.0) 4 (2.7) 4 (1.2) 3 (2.6)
Sepsis 3 (1.0) 10 (6.8) 3 (0.9) 10 (8.6)
Septic shock 0 (0.00) 1 (0.7) 0.0012 0 (0.0) 1 (0.9) \0.0001
Smoking, n (%)
Active 92 (30.9) 44 (29.9) 107 (32.7) 29 (24.8)
Prior 52 (17.5) 44 (29.9) 60 (18.4) 36 (30.8)
Never 135 (45.5) 47 (31.9) 0.0072 141 (43.1) 41 (35.0) 0.012
Alcohol consumption, n (%)
[Recommendationsa 16 (5.4) 17 (11.6) 20 (6.1) 13 (2.9)
\Recommendationsa 281 (94.6) 130 (88.4) 0.020 307 (93.9) 104 (88.9) 0.08
Degree of care, n (%)
Independent 269 (90.6) 89 (61.4) 298 (91.1) 60 (52.2)
Partially dependentb 19 (6.4) 27 (18.6) 20 (6.1) 26 (22.6)
Fully dependent 9 (3.0) 29 (20.0) \0.0001 9 (2.8) 29 (25.2) \0.0001
Triage categoryc, n (%)
Green 98 (31.5) 32 (22.4) 100 (31.1) 24 (21.2)
Yellow 107 (36.6) 35 (24.5) 113 (35.1) 29 (25.7)
Orange 80 (27.4) 71 (49.7) 93 (28.9) 58 (51.3)
Red 13 (4.5) 5 (3.5) 0.0001 16 (4.9) 2 (1. 8) 0.0002
COPD, n (%) 13 (4.4) 14 (9.5) 0.033 9 (2.8) 18 (15.4) \0.0001
Diabetes, n (%) 21 (7.1) 17 (11.6) 0.11 15 (4.6) 23 (19.7) \0.0001
Heart failure, n (%) 2 (0.7) 10 (6.8) 0.0002 1 (0.3) 11 (9.4) \0.0001
Stroke, CVA, n (%) 21 (7.1) 36 (24.5) \0.0001 22 (6.7) 35 (29.9) \0.0001
Hypertension, n (%) 52 (17.5) 48 (32.6) 0.0003 51 (15.6) 49 (41.9) \0.0001
Cancer, n (%) 13 (4.4) 13 (8.8) 0.06 10 (3.1) 16 (13.7) \0.0001
suPAR (ng/mL), mean (SD) 3.9 (0.9) 8.2 (3.7) 4.6 (1.9) 7.4 (4.3)
BMI body mass index, COPD chronic obstructive pulmonary disease, SIRS systemic inflammatory response syndrome, suPAR soluble urokinase
plasminogen activator receptor, CVA cerebrovascular accident
aDanish recommendations 2013: women B 14 and men B 21 units of alcohol weekly
bPartially dependent: any degree of home care
cGreen/yellow/orange/red refers to triage acuity level: non-urgent/urgent/emergent/resuscitation, respectively
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Analysis and statistics
Patients were stratified into groups according to suPAR
tertiles and ASA classification. A binary classification of
suPAR level and ASA classification was constructed. The
1st and 2nd suPAR tertiles were classified as suPARlow
(n = 297, suPAR B 5.5 ng/ml), and patients in the 3rd
tertile were classified as suPARhigh (n = 147, suPAR[
5.5 ng/ml). Patients were distributed unequally in ASA
categories (ASA I: 148, ASA II: 179, ASA III: 110, ASA
IV: 6, and ASA V: 1) patients with an ASA classifica-
tion B II were classified as ASAlow (n = 327) and patients
with an ASA classification C III were classified as ASAhigh
(n = 117). This stratification of suPAR level and ASA
classification resulted in comparable groups sizes.
Continuous data are presented as mean with standard
deviation (SD), and categorical data are presented as n (%).
Baseline characteristics were compared using Student’s
t test and Chi-square test. Interrater agreement was asses-
sed using Cohen’s Kappa coefficient. Univariate and mul-
tivariate logistic regression analyses were used to estimate
odds ratios (ORs) with 95% confidence intervals (CIs)
presented in forest plots. Similarly, univariate and multi-
variate Cox regression analyses were used to estimate
hazard ratios (HRs) with 95% CI for log2-transformed
suPAR levels or log10-transformed CRP levels. Postoper-
ative mortality within 90 days is presented in Kaplan–
Meier plots for suPAR level and ASA classification. Pre-
dictive capabilities of ASA classification and suPAR level,
regarding any endpoint, are presented in area under the
curve (AUC). P values\ 0.05 were considered statistically
significant.
Graphs were created with GraphPad Prism 7.02.197
(GraphPad software) and R 3.2.3 (R Foundation for Sta-
tistical Computing). All statistical analyses were performed
using SAS Enterprise guide 7.12 (SAS Institute) and R
3.2.3.
Ethics
The study was conducted according to Danish legislation,
and it was approved by the Danish Data Protection agency
(ref. no. 2007-58-0015).
Consent
Regarding consent from patients, formal ethical approval
was not necessary for this study. The TRIAGE study
compiled all data in a central server. All patients were
pseudo-anonymized, but with a unique patient number.
Patient data could afterward be cross referenced with
Danish registries. This procedure is in accordance with
ethical regulations.
Results
Baseline characteristics
The TRIAGE study included 5302 acutely admitted
patients (6005 admission). Of these, 697 (13.2%) had any
surgical intervention registered within 90 days after
admission and were included in the current study. Exclu-
sion criteria were: no suPAR measurement (n = 45),
Table 2 Postoperative complications according to suPARlow/high (above or below 5.5 ng/ml) and ASAlow/high groups (ASA I/II and III or above)
Variable suPARlow suPARhigh P ASAlow ASAhigh P
n (%) 297 (66.9) 147 (33.1) 327 (73.7) 117 (26.4)
All endpointsa 74 (24.9) 84 (57.1) \0.0001 83 (25.4) 75 (64.1) \0.0001
Reoperation 27 (9.1) 32 (21.8) 0.0002 34 (10.4) 25 (21.4) 0.0027
Urinary tract infection 19 (6.4) 28 (19.1) \0.0001 27 (8.3) 20 (17.1) 0.0077
Pneumonia 14 (4.7) 24 (16.3) \0.0001 15 (4.6) 23 (19.7) \0.0001
Sepsis 5 (1.7) 23 (15.7) \0.0001 7 (2.1) 21 (17.9) \0.0001
Surgical site infection 22 (7.4) 22 (14.9) 0.012 24 (7.3) 20 (17.1) 0.0024
Transfusion 5 (1.7) 11 (7.5) 0.0020 6 (1.8) 10 (8.6) 0.0008
Other complicationsb 12 (4.0) 20 (13.6) 0.0002 9 (2.8) 23 (19.7) \0.0001
Death 4 (1.4) 27 (18.6) \0.0001 6 (1.9) 25 (21.4) \0.0001
ASA The American Society of Anesthesiologists classification, suPAR soluble urokinase plasminogen activator receptor
aDefined as death, reoperation, or any of the 20 predefined postoperative complications
bOther complications (n): acute kidney failure (n = 4), atelectasis (n = 10), cardiac arrest and CPR (n = 3), ileus (n = 6), intra/postoperative
myocardial infarction (n = 0), intra/postoperative pulmonary embolism (n = 0), intra/postoperative unplanned intubation (n = 6), progressive
kidney failure (n = 0), septic shock (n = 4), stroke/cerebrovascular injury (n = 1), venous thrombosis requiring treatment (n = 3) and wound
rupture (n = 3)
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patients admitted as surgical patients, but received no
surgical intervention (n = 151) and no ASA classification
registered (n = 57). The final population comprised 444
patients (8.4%).
In the final study population, the mean age was 61 years
(SD 20.9) (Table 1). Mean suPAR level was 5.3 ng/ml (SD
3.0). The 444 surgical interventions included general sur-
gery (n = 184, 41.4%), orthopedic surgery (n = 184,
41.4%), and other (n = 76, 17.2%), which covered uro-
logic, gynecologic, and cardiovascular procedures.
Patients in suPARhigh and ASAhigh were older, had
higher rates of various comorbidities, were more frequently
smokers, had higher triage level at admission, received a
higher degree of home care, underwent larger surgical
interventions, and presented more frequently with
preoperative SIRS/sepsis compared with suPARlow and
ASAlow, respectively (Table 1).
High ASA classification and high suPAR level are
associated with endpoints
Within 90 days after surgery, 31 (7.0%) patients had died,
and a total of 158 (35.6%) patients had a postoperative
complication (Table 2).
Patients in suPARhigh and ASAhigh had significantly
higher rates of mortality, reoperation, urinary tract infec-
tion (UTI), pneumonia, sepsis, surgical site infection (SSI),
and transfusion compared to suPARlow and ASAlow,
respectively (Table 2).
Fig. 1 Kaplan–Meier plot showing 90 days postoperative survival
in surgical patients stratified by a ASA classification I–III? and
b suPAR levels in tertiles. Mortality rates in groups, n (%): a ASA I:
0 (0%), ASA II: 6 (19%), and ASA III?: 25 (81%). b suPAR tertile
1: 0 (0%) with a mean suPAR level of 3.14 ng/ml (SD 0.47), suPAR
tertile 2: 4 (13%) with a mean suPAR level of 4.62 ng/ml (SD 0.51),
and suPAR tertile 3: 27 (87%) with a mean suPAR level of 8.21 ng/
ml (SD 3.65)
Fig. 2 Forest plot showing most frequently occurring postoperative
complications. Odds ratios (95% CI) for a univariate analyses and
b multivariate analyses adjusted for sex, age, and suPAR level
(above or below 5.5 ng/ml) or ASA classification (ASA I/II and III
or above), with the dotted line as reference
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Kaplan–Meier plots illustrate the increased risk of
postoperative mortality in all surgical specialties combined
for patients with high ASA classification or suPAR level
(Fig. 1).
Univariate ORs for all endpoints were significantly
higher in suPARhigh and ASAhigh compared to suPARlow or
ASAlow, respectively (Fig. 2). For the following endpoints,
OR (95% CI) were highly significant (P\ 0.0001) for
suPAR level and ASA classification, respectively: sepsis
10.8 (4.0–29.1) and 10.0 (4.1–24.2); mortality 16.5
(5.7–48.3) and 14.3 (5.7–35.8); and for any endpoint 4.0
(2.6–6.1) and 5.3 (3.3–8.3). The association between high
suPAR level and mortality, sepsis, reoperation, or any
endpoint remained significant after adjusting for sex, age,
and ASA classification (Fig. 2). The association between
high ASA classification and sepsis, pneumonia, mortality,
or any endpoint remained significant after adjusting for sex,
age, and suPAR level.
Cox regression analysis of 90-day postoperative mor-
tality using continuous log2-transformed suPAR levels
resulted in a univariate HR of 4.5 (95% CI 3.2–6.4), and
suPAR remained an independent predictor of 90-day
mortality with a HR of 2.5 (95% CI 1.6–4.0) after adjusting
for sex, age, and ASA classification.
Sensitivity analyses of Cox models regarding
mortality
Postoperative mortality within 90 days in individual ASA
groups was: ASA I: no deaths; ASA II: six deaths (3.4%);
ASA III?: 25 deaths (29.3%). In a Cox model for 90 days
postoperative mortality, HRs for log2-transformed suPAR
in individual ASA groups were 4.4 (95% CI 1.1–18.5) for
ASA II and 2.9 (95% CI 1.3–6.1) for ASA III? after
adjusting for age, sex, and log10-transformed CRP.
Time from admission to surgery was median 1 day (IQR
0–3 days). When controlling for time to surgery, in addi-
tion to sex, age, and ASA, log2-transformed suPAR
remained an independent predictor for 90 days postopera-
tive mortality with a HR of 2.6 (95% CI 1.6–4.0).
Association between ASA classification and suPAR
level
We investigated the agreement between low and high ASA
classification with low and high suPAR level and the cat-
egorization of postoperative mortality and obtained a
Kappa interrater agreement of 0.38, defined as fair [28]
(Fig. 3). The median suPAR levels increased with higher
ASA classification: ASA I: 3.5 ng/ml (3.0–4.5); ASA II:
4.6 ng/ml (3.7–6.0); ASA III?: 6.2 ng/ml (4.8–8.9)
P\ 0.0001. No patients died (0%) in the category
ASAlow/suPARlow (n = 250); four patients (9.3%) died in
the category ASAhigh/suPARlow (n = 39); six patients
(8.5%) died in the category ASAlow/suPARhigh (n = 65);
and 21 patients (28.4%) died in the category ASAhigh/
suPARhigh (n = 53); P\ 0.0001 (Fig. 3).
Association between suPAR and CRP
suPAR and CRP were positively correlated (Kendall’s tau-
b r = 0.10, P = 0.0046) (Supplementary Fig. 1). The
median (IQR) CRP level increased in higher ASA cate-
gories: ASA I: 9.1 mg/L (2.9–38.3); ASA II: 9.7 mg/L
(2.9–34.0); and ASA III?: 20.0 mg/L (4.2–85.0). CRP
levels were also predictive of 90 days postoperative mor-
tality with a HR of 2.8 (95% CI 1.6–5.0); however, this
association became insignificant when adjusted for age,
sex, ASA and log2-suPAR, HR 1.7 (95% CI 0.9–3.1).
In comparison, suPAR remained predictive of 90 days
postoperative mortality HR 3.4 (95% CI 1.7–6.8) when
adjusted for age, sex, ASA, and CRP.
CRP was also predictive of mortality (Supplementary
Fig. 2) and complications in ROC analyses (Table 3);
however in all patients, suPAR was significantly better at
predicting mortality and all complications (P = 0.0036 and
P = 0.0041, respectively).
Predictive capabilities of ASA classification, suPAR
Level, and ASA classification and suPAR level
combined
To evaluate the predictive capabilities for all complications
across different specialties, ROC curve analyses were
performed for ASA classification, suPAR level, or the
Fig. 3 Kaplan–Meier plot showing 90 days postoperative survival
in surgical patients categorized by combining ASAhigh/low and
suPARhigh/low groups, respectively, according to suPAR level
(above or below 5.5 ng/ml) or ASA classification (ASA I/II and
III or above)
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combination of ASA classification and suPAR level (Fig. 4
and Table 3).
The suPAR level and ASA classification had approxi-
mately the same predictive value for all endpoints across
all specialties. Combining the ASA classification and the
suPAR level increased the AUCs (Fig. 4 and Table 3). The
combined model was significantly better than using suPAR
or ASA individually for all surgical patients to 0.74 (95%
CI 0.69–0.79) (P: combined vs. ASA: 0.002, combined vs.
suPAR: 0.009)
For suPAR levels, ROC curves predicting 90 days
mortality showed an AUC of 0.87 (95% CI 0.82–0.92) for
all surgical patients, compared with ASA and CRP which
had AUCs of 0.83 (95% CI 0.77–0.88) and 0.70 (95% CI
0.60–0.80), respectively (Supplementary Fig. 2, Table 3).
Table 3 Overview of predictive capabilities of suPAR, ASA, CRP, ASA and suPAR combined and ASA and CRP combined
ASA suPAR CRP ASA ? suPAR ASA ? CRP P
ASA ? suPAR
versus ASA
? CRP
All complications
General 0.68 (0.60–0.77) 0.68 (0.58–0.77) 0.55 (0.45–0.65) 0.70 (95% CI
0.62–0.80)
0.70 (0.60–0.79) 0.89
Orthopedic 0.71 (0.64–0.78) 0.71 (0.63–0.78) 0.63 (0.55–0.72) 0.75 (95% CI
0.68–0.82)
0.72 (0.64–0.79) 0.45
Othera 0.68 (0.55–0.80) 0.65 (0.51–0.78) 0.71 (0.58–0.85) 0.71 (95% CI
0.58–0.84)
0.77 (0.64–0.89) 0.49
All 0.71 (0.66–0.76) 0.70 (0.65–0.75) 0.58 (0.53–0.64) 0.74 (95% CI
0.69–0.79
0.72 (0.67–0.77) 0.55
Versus
ASA ? suPAR
P\ 0.001
Versus
ASA ? suPAR
P = 0.009
Versus
ASA ? CRP
P\ 0.001
ASA ? CRP
P = 0.70
Post OP mortality
General 0.92 (0.89–0.95) 0.95 (95% CI
0.90–1.00
0.67 (0.44–0.90) 0.97 (0.94–1) 0.93 (0.89–0.98) 0.2
Orthopedic 0.74 (0.64–0.84) 0.80 (95% CI
0.71–0.90)
0.71 (0.57–0.85) 0.84 (0.76–0.91) 0.79 (0.69–0.89) 0.49
Other 0.84 (0.73–0.95) 0.87 (95% CI
0.77–0.98)
0.89 (0.81–0.97) 0.90 (0.83–0.98) 0.89 (0.79–0.99) 0.84
All 0.83 (0.77–0.88) 0.87 (95% CI
0.82–0.92)
0.70 (0.6–0.80). 0.90 (0.86–0.94) 0.86 (0.80–0.92) 0.23
Versus
ASA ? suPAR
P\ 0.001
Versus
ASA ? suPAR
P = 0.15
Versus
CRP ? ASA
P\ 0.01
Versus ASA ? CRP
P = 0.44
Complications
without mortality
General 0.69 (0.59–0.79) 0.64 (95% CI
0.54–0.74)
0.55 (0.45–0.66) 0.69 (0.58–0.79) 0.70 (0.59–0.80) 0.2
Orthopedic 0.70 (0.63–0.77) 0.69 (95% CI
0.61–0.77)
0.60 (0.52–0.69) 0.74 (0.67–0.81) 0.71 (0.63–0.79) 0.49
Other 0.71 (0.57–0.85) 0.66 (95% CI
0.50–0.81)
0.63 (0.46–0.80) 0.74 (0.60–0.88) 0.78 (0.63–0.92) 0.84
All 0.71 (0.66–0.76) 0.69 (95% CI
0.63–0.74)
0.56 (0.5–0.63). 0.74 (0.69–0.79) 0.78 (0.66–0.77) 0.23
aOther surgical specialties cover urologic, gynecologic, and cardiovascular procedures
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Discussion
In this sub-study of surgical patients admitted during the
TRIAGE study, we aimed to evaluate the blood level of the
biomarker suPAR in the prediction of postoperative com-
plications. We found that suPAR was significantly associ-
ated with the occurrence of postoperative complications.
suPAR was equally as good as the ASA classification in
predicting endpoints in all surgical patients, and better at
predicting mortality and all complications compared to
CRP. Adding suPAR to the ASA classification significantly
improved prediction of all endpoints compared with ASA
classification alone.
Globally, the ASA classification is commonly used for
risk stratifying surgical patients [29]. The ASA classifica-
tion has been criticized for its subjectivity, inter-observer
variability, and inconsistency in classifying patients prior
to surgery [30–33]. Particularly, the classification of ASA
class II and III is characterized by a considerable dis-
agreement between physicians [30]. Various preoperative
risk assessment models have been developed to improve
identification of patients at high risk of morbidity and
mortality [27, 33–35]. These risk models also have limi-
tations; for example the Physiologic and Operative Sever-
ity Score for the enUmeration of Mortality and Morbidity
(POSSUM) score require intra- and postoperative infor-
mation and has inaccurate estimates of mortality risk [36];
the American College of Surgeons National Surgical
Quality Improvement Program (ACS-NSQIP) requires
consideration of numerous variables, making it is difficult
to apply in the acute setting [37]. Therefore, these models
are not commonly used in the preoperative risk assessment,
Fig. 4 Receiver operating
characteristic (ROC) curves for
suPAR level, ASA
classification, and suPAR level
and ASA classification
combined for prediction of any
endpoint according to surgical
specialties or all patients. AUCs
(95% CI): general surgery:
suPAR 0.68 (0.58–0.77), ASA
0.68 (0.60–0.77), combined
0.70 (0.62–0.80). Orthopedic
surgery: suPAR 0.71
(0.63–0.78), ASA 0.71
(0.64–0.78), combined 0.75
(0.68–0.82). Other: suPAR 0.65
(0.51–0.78), ASA 0.68
(0.55–0.80), combined 0.71
(0.58–0.84). All patients:
suPAR 0.70 (0.65–0.75), ASA
0.71 (0.66–0.76), combined
0.74 (0.69–0.79) (P values:
combined vs. ASA 0.002.
Combined vs. suPAR 0.009)
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because they are complicated, time-consuming, and mul-
tivariate in nature. Other simpler models add predictive
value to the ASA classification; for example, the Surgical
Mortality Probability Model and a similar model proposed
by Glance and Donati [4, 6]. But a common feature is that
risk assessment models are poorly supported by biochem-
ical analyses.
There are numerous advantages in identifying a func-
tional, simple, biochemically assisted, bedside model for
preoperative risk scoring of surgical patients. It could
enable identification of patients who will need a higher
level of pre-, intra-, and postoperative care, and this may
decrease the rate of postoperative mortality and morbidity.
suPAR could potentially play a role in the development of
an accurate, affordable, and clinically sufficient preopera-
tive bedside model.
CRP is often used postoperatively to provide early
detection of surgical infections, anastomotic leakage, and
other postoperative events, and CRP is affected by surgical
trauma [38–40].
suPAR is a stable biomarker of low-grade inflammation,
associated with development and presence of various dis-
eases, and has shown to provide prognostic value as a
biomarker in acute medical patients [14, 15, 17, 20, 21]. It
has been shown that the predictive value of suPAR is
present years before the development of disease, and
suPAR is stable during an early inflammatory state and
surgical trauma [41, 42]. These properties could benefit the
preoperative risk assessment by reflecting the overall
inflammatory state of the patient, independent of the
underlying pathologies or reasons for surgery.
The 3rd suPAR tertile had the highest mortality rate,
accounting for 87% of all deaths in the cohort and more
than doubled the amount of overall endpoints compared
with the 1st and 2nd tertiles combined, and patients in
either ASAhigh or suPARhigh groups had higher mortality
rates, compared to patients in ASAlow and suPARlow
groups.
Comparing the predictive capabilities of suPAR, ASA,
or CRP alone and in unity shows that suPAR has an overall
better prediction of complications and mortality than CRP
and ASA in all specialties combined, general-, and ortho-
pedic surgery. When adjusting for age, sex, ASA and CRP,
suPAR’s HR was largely unaffected compared to CRP
which was greatly weakened. This could indicate the dif-
ference in predictive capabilities between an acute phase
reactant and a more stable unspecific biomarker.
As various lifestyle changes, pharmacological- and
surgical treatment have been shown to result in lower
suPAR levels [20, 43], it is possible that interventions
leading to a reduction in a patient’s suPAR level prior to
surgery could potentially lower the risk of postoperative
complications.
Limitations
This is a retrospective, single-center, medical record- and
registry-based sub-study to the TRIAGE study and is
therefore dependent on the thoroughness in the registration
of complications. Some complications may not have been
registered, masked by more severe complications, or
remained unnoticed. Lack of registration would underes-
timate the number of complications and therefore have an
impact on the ability to predict those events.
We only had access to the results of the blood samples
drawn at admission, and all included patients underwent
surgery within 90 days of admission. In future prospective
studies, blood samples drawn prior to, during surgery and
samples postoperatively should be investigated, to clarify
whether suPAR levels change during surgery, or if changes
in suPAR levels could add predictive value
postoperatively.
In our study, a small number of patients were classified
as ASA III (25%), IV (1%) or ASA V (\1%). To compare
suPAR levels and ASA classification, we stratified patients
in high/low groups. As a result, some of the discriminatory
capabilities of suPAR might be lost. Therefore, in future
studies, it could be beneficial to include more patients with
ASA classifications III, IV and V and examine the impact
of continuous suPAR levels.
This study was designed and executed at the Department
of Cardiology, Herlev hospital, parallel to studies investi-
gating suPAR’s predictive capabilities in medical patients.
Surgeons were consulted, but the expertise of surgical
departments and staff should be included in the design and
execution of future prospective studies on this topic.
This study does not consider the experience of the
operating surgeon, or whether surgery was acute or not. In
addition, the time interval between admission, subsequent
suPAR measurement, and the surgical intervention varied
among patients. These factors could be standardized in a
future study.
Lastly, we only compared suPAR to the ASA classifi-
cation. Additional studies are needed to determine whether
suPAR could be a part of a smaller risk model in compe-
tition with or add predictive value to other risk scores, such
as POSSUM, ACS-NSQIP, etc.
Conclusion
suPAR levels can independently predict postoperative
complications and mortality. suPAR can significantly
improve the predictive capabilities of the preoperative risk
assessment of surgical patients performed with the ASA
classification. Specifically, regarding mortality, suPAR
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levels add a potentially valuable predictive addition.
However, an interventional study is needed to determine
whether preoperative risk assessment with the addition of
suPAR can reduce postoperative complications and
mortality.
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